Headlands Technologies LLC Has $562,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Key Points

• Headlands Technologies LLC reduced its investment in TransMedics Group, Inc. by 25.8% during the first quarter, maintaining a holding of 8,357 shares worth approximately $562,000.
• TransMedics Group reported a strong quarterly earnings result, with earnings per share of $0.92, significantly exceeding analyst expectations of $0.48 and a year-over-year revenue increase of 37.7%.
• Recent analyst ratings for TransMedics Group show a mix of recommendations, including upgrades from firms like Canaccord Genuity and Oppenheimer, with an average target price of $123.00.

Headlands Technologies LLC lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 25.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,357 shares of the company's stock after selling 2,903 shares during the quarter. Headlands Technologies LLC's holdings in TransMedics Group were worth $562,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. CWM LLC boosted its stake in TransMedics Group by 20.1% during the first quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after buying an additional 155 shares in the last quarter. Campbell Newman Asset Management Inc. lifted its holdings in shares of TransMedics Group by 1.4% during the first quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock valued at $782,000 after purchasing an additional 166 shares during the last quarter. Hager Investment Management Services LLC lifted its holdings in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after purchasing an additional 205 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of TransMedics Group by 1.6% during the first quarter. Nisa Investment Advisors LLC now owns 15,824 shares of the company's stock valued at $1,065,000 after purchasing an additional 256 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of TransMedics Group by 13.8% during the first quarter. PNC Financial Services Group Inc. now owns 2,294 shares of the company's stock valued at $154,000 after purchasing an additional 278 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

TMDX has been the subject of several analyst reports. Wall Street Zen raised TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Morgan Stanley increased their price objective on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Oppenheimer increased their price objective on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Finally, Canaccord Genuity Group increased their price objective on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and a consensus price target of $123.00.

TransMedics Group Stock Up 1.4%

Shares of TMDX traded up $1.78 during midday trading on Wednesday, reaching $132.91. 516,293 shares of the stock were exchanged, compared to its average volume of 1,353,218. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a 50 day simple moving average of $123.96 and a 200-day simple moving average of $98.35. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The company has a market cap of $4.53 billion, a price-to-earnings ratio of 68.85 and a beta of 2.09.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%. The business's quarterly revenue was up 37.7% on a year-over-year basis. During the same period last year, the business earned $0.35 EPS. Research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Activity

In other news, Director David Weill sold 732 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director owned 12,134 shares of the company's stock, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,418 shares of company stock valued at $818,833. Insiders own 7.00% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.